{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:18Z","timestamp":1788250458304,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>First\u2010line platinum\u2010based therapy for advanced squamous cell carcinomas of the anal canal (SCCA) implies a risk of substantial side effects, and data on second\u2010line treatment options are limited. Paclitaxel and Capecitabine are a well\u2010known regimen with a moderate toxicity profile, but its efficacy has not been evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study using Danish Hospital Registers of patients treated with Paclitaxel and Capecitabine for inoperable, recurrent, or advanced metastatic SCCA in Denmark, between January 2000 and July 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 52 patients met the eligibility criteria. Median age was 60.7\u00a0years (range 42\u201383). Efficacy was observed, with an overall response rate in patients receiving first\u2010line (<jats:italic>N<\/jats:italic>\u00a0=\u00a028) and second\u2010line (<jats:italic>N<\/jats:italic>\u00a0=\u00a023) Paclitaxel and Capecitabine of 39.3% (2 with complete responses) and 17.4%, respectively. Median progression\u2010free survival (PFS) was 4.5\u00a0months (95% CI 3.3\u20135.9) and 3.8\u00a0months (95% CI 2.4\u20135.5) with OS of 6.7\u00a0months (95% CI 5.9\u20138.5) and 5.9\u00a0months (95% CI 3.9\u201314), respectively. Performance status \u22652 and neutrophil to lymphocyte ratio \u22654 were significantly associated with a short PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study recognizes Paclitaxel and Capecitabine as a potential regimen for advanced SCCA, when recommended first\u2010line therapy is not feasible or as a potential second\u2010line treatment after failure of platinum\u2010based chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.3886","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T23:18:52Z","timestamp":1620515932000},"page":"3224-3230","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nonplatinum\u2010based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population\u2010based Danish anal cancer group study"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-3644","authenticated-orcid":false,"given":"Christina Glismand","family":"Truelsen","sequence":"first","affiliation":[{"name":"Department of Oncology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Serup\u2010Hansen","sequence":"additional","affiliation":[{"name":"Department of Oncology Herlev and Gentofte Hospital Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine Smedegaard","family":"Storm","sequence":"additional","affiliation":[{"name":"Department of Oncology Herlev and Gentofte Hospital Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Mayland","family":"Havelund","sequence":"additional","affiliation":[{"name":"Department of Oncology at Vejle Hospital University Hospital of Southern Denmark Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Skovhus","family":"Kronborg","sequence":"additional","affiliation":[{"name":"The Danish Center for Particle Therapy Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-3212","authenticated-orcid":false,"given":"Karen\u2010Lise Garm","family":"Spindler","sequence":"additional","affiliation":[{"name":"Department of Experimental Clinical Oncology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Anal Cancer \u2014 Cancer Stat Facts. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html"},{"issue":"3","key":"e_1_2_11_3_1","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami F","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205105"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083882"},{"issue":"10","key":"e_1_2_11_6_1","first-page":"861","article-title":"Carcinome epidermoide metastatique de l\u2019anus: etude retrospective de l\u2019efficacite de l\u2019association de 5\u2010fluoro\u2010uracile en perfusion continue et de cisplatine","volume":"86","author":"Faivre C","year":"1999","journal-title":"Bull Cancer"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0241"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2563"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"viii715","DOI":"10.1093\/annonc\/mdy424.022","article-title":"InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5\u2010fluorouracil (5\u2010FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment na\u00efve disease \u2013 An International Rare Cancers Initiative (IRCI) trial","volume":"29","author":"Rao S","year":"2018","journal-title":"Ann Oncol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0698-6"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3408-4"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00243"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.425"},{"issue":"4","key":"e_1_2_11_14_1","article-title":"Schedule dependency of antitumor activity in combination therapy with Capecitabine\/5\u2032\u2010Deoxy\u20105\u2010fluorouridine and docetaxel in breast cancer models","volume":"7","author":"Fujimoto\u2010Ouchi K","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1043026"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000361051"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.4_suppl.728"},{"issue":"12","key":"e_1_2_11_20_1","first-page":"4637","article-title":"Single\u2010agent paclitaxel in advanced anal cancer after failure of cisplatin and 5\u2010fluorouracil chemotherapy","volume":"31","author":"Abbas A","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001457"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2558"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/codi.12467"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3886","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.3886","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.3886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T02:44:33Z","timestamp":1693622673000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.3886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/cam4.3886"],"URL":"https:\/\/doi.org\/10.1002\/cam4.3886","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}